RTX-500

RTX-500 is an antibody-based therapeutic candidate currently in preclinical development by Resonant Therapeutics. It is designed to target an unspecified immune regulator for the treatment of lymphoma and pancreatic cancer. Discovered through Resonant's proprietary platform, which identifies functionally active antibodies and novel targets within the tumor microenvironment, RTX-500 aims to modulate immune responses to combat malignancy. While the specific molecular target has not been disclosed, the candidate is part of a pipeline that explores various antibody formats, including naked antibodies, antibody-drug conjugates (ADCs), and bispecific antibodies, to optimize therapeutic efficacy in solid and hematologic tumors.